Nicholas Firth, Head of Trading and Portfolio Manager for Xantium Group, presented an investment idea in the biotechnology and neuroscience sector at the 2025 Sohn London Conference. Firth, who leads Xantium’s biotech portfolio, has a highly technical background, having completed a PhD at the Institute of Cancer Research focusing on applying machine learning and evolutionary algorithms to drug design. He also worked at University College London using mathematical modeling to develop the diagnosis and monitoring of Alzheimer's disease. Xantium Group is a trading name in the UK of Tudor Capital Europe LLP.
Also see:
2025 Sohn London Conference: Xantium Group’s Nicholas Firth
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
